Abstract:The application of population approaches to drug development is recommended in several US Food and Drug Administration (Fl)A) guidance documents. Population pharmacokinetic (and pharmacodynamic) techniques enable identification of the sources of inter- and intra-individual variability that impinge. upon drug Safety and efficacy. This article briefly discusses the 2-stage approach to the estimation of population pharmacokinetic parameters, which requires serial multiple measurements on each participant, and comprehensively reviews the nonlinear mixed-effects. modelling approach, which can be applied in situations where extensive sampling is not done on all or any of the participants.Certain preliminary information, such as the compartment model used in describing the pharmacokinetics of the drug, is required for a population pharmacokinetic study. The practical design considerations of the location of sampling times, number of samples/participants and the need to sample an individual more than once should be borne in mind. Simulation may be useful for choosing the study design that will best meet study objectives.The objectives of the population pharmacokinetic study can be secondary to the objectives of the primary clinical study lin which case an add-on population pharmacokinetic protocol may be needed) or primary (when a stand-alone protocol is required). Having protocols for population pharmacokinetic studies is an integral part of 'good pharmacometric practice'.Real-time data assembly and analysis permit an ongoing evaluation of site compliance with the study protocol and provide the opportunity to correct violations of study procedures. Adequate policies and procedures should be in place for study blind maintenance. Real-time data assembly creates the opportunity for detecting and correcting errors in concentration-time data, drug administration history and covariate data.Population pharmacokinetic analyses may be undertaken in 3 interwoven steps: exploratory data analysis, model development and model validation (i.e. predictive performance). Documentation for regulatory purposes should include a complete inventory of key runs in the analyses undertaken (with flow diagrams if possible), accompanied by articulation of objectives, assumptions and hypotheses. Use of diagnostic analyses of goodness of fit as evidence of reliability of results is advised. Finally, the use of stability testing or model validation may be warranted to support label claims.The opinions expressed in this article were revised by incorporating comments from various sources and published by the FDA as 'Guidance for Industry: Population Pharmacokinetics' (see the FDA home page http://www.fda.gov for further information).

A pharmacokinetic analysis program (multi) for microcomputer

MULTI-FORTE, a microcomputer program for modelling and simulation of pharmacokinetic data

A nonlinear least squares program based on differential equations, MULTI (RUNGE), for microcomputers

Nonlinear least-squares regression analysis by a simplex method using differential equations containing Michaelis-Menten type rate constants

PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel

CPhaMAS: An Online Platform for Pharmacokinetic Data Analysis Based on Optimized Parameter Fitting Algorithm

A versatile implementation of the Gauss-Newton minimization algorithm using MATLAB for Macintosh microcomputers

On-line Monitoring of Penicillin Cultivation Process Based on Multi-way Partial Least Squares

A new algorithm for computing the parameters of linear compartment models in pharmacokinetics

A series acceleration algorithm for the gamma-Pareto (type I) convolution and related functions of interest for pharmacokinetics

Analysis of multidrug effects by parameter method

On - line statistical monitoring and production quality control of penicillin cultivation process

A fully automatic tool for development of population pharmacokinetic models

One-compartment Model with Michaelis-Menten Elimination Kinetics and Therapeutic Window: an Analytical Approach.

Application of a Mixed Algorithm Based on GA and Gauss-Newton Algorithm in Analysis of Biokinetic Data of Radiopharmaceuticals

Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models

Computer aided optimization of multilinear gradient elution in liquid chromatography

PC-based differential model fitting as a support for clinical research

Population Pharmacokinetics - A Regulatory Perspective

An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approach

Application of computer on Pharmacogenomics